Pharmaceuticals

Ausun Pharm

Ausun Pharm released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 308.67 M, actual EPS CNY 0.12

Ausun Pharm released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 146.8 M, actual EPS CNY -0.098

Ausun Pharm released FY2025 annual earnings on April 28 After-Market BJT, actual revenue CNY 792.76 M (forecast CNY 846 M), actual EPS CNY 0.16 (forecast CNY 0.265)

Ausun Pharm FY2026 Q1 Earnings Release on April 29 After-Market BJT

Ausun Pharm to release FY2025 earnings on April 29 After-Market BJT, forecast revenue CNY 846 M, EPS CNY 0.265

Ausun Pharm released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 645.96 M, actual EPS CNY 0.2472

Ausun Pharm released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 164.09 M, actual EPS CNY 0.0476

Ausun Pharm FY2025 Q3 Earnings Release on October 31 After-Market BJT

Ausun Pharm released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue CNY 175.24 M, actual EPS CNY 0.0595

Ausun Pharm released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue CNY 481.87 M, actual EPS CNY 0.2

Ausun Pharm to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Oxane Pharmaceutical's Imatinib Mesylate Tablets Are the World's First Anti-Tumor Molecular Targeted Drug

AoXiang Pharmaceutical Introduces Progress in Developing Innovative Drugs

AoXiang Pharmaceutical Releases 2025 Q1 Financial Report

Ausun Pharm released FY2024 earnings on April 29 After-Market (BJT), actual revenue CNY 795.29 M (forecast CNY 907 M), actual EPS CNY 0.25 (forecast CNY 0.35)

Ausun Pharm released FY2024 Q4 earnings on April 29 After-Market (BJT), actual revenue CNY 105.16 M, actual EPS CNY -0.0259

Ausun Pharm released FY2025 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 306.64 M, actual EPS CNY 0.14

Ausun Pharm FY2025 Q1 Earnings Release on April 30, Pre-Market BJT

Ausun Pharm to release FY2024 earnings on April 30 After-Market (BJT), forecast revenue CNY 907 M, EPS CNY 0.35

Aoxiang Pharmaceutical Receives European Pharmacopoeia Certification for Pilocarpine Raw Material

603229

Ausun Pharm announced that as of October 31, 2025, the company has repurchased a total of 5.2012 million shares, with a total payment of 50.006 million yuan, and the repurchase price ranged from 7.52 yuan/share to 11.39 yuan/share. The repurchase plan was initiated on January 24, 2025, with an expected funding usage of 50 million to 100 million yuan, and the repurchase period will last until January 23, 2026. Due to the annual equity distribution in 2024, the upper limit of the repurchase price will be adjusted to no more than 13.90 yuan/share starting from July 17, 2025

Zhitong

Ausun Pharm: Has repurchased a total of 5.2012 million shares, amounting to 50.006 million yuan

According to the Zhitong Finance APP, Ausun Pharm disclosed its third-quarter report for 2025. The company achieved revenue of 646 million yuan in the first three quarters, a year-on-year decrease of 6.40%; net profit attributable to the parent company was 207 million yuan, a year-on-year decrease of 9.59%; net profit excluding non-recurring gains and losses was 183 million yuan, a year-on-year decrease of 13.83%; basic earnings per share were 0.25 yuan

Ausun Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 207 million yuan, a year-on-year decrease of 9.59%

Ausun Pharm's wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Imatinib Mesylate Tablets issued by the National Medical Products Administration. This drug is the world's first molecular targeted therapy for tumors, primarily used to treat chronic myeloid leukemia and malignant gastrointestinal stromal tumors. The active ingredient, Imatinib, is a tyrosine kinase inhibitor that can inhibit the proliferation of abnormal white blood cells

Ausun Pharm: Imatinib Mesylate Tablets Obtained Drug Registration Certificate

According to the Zhitong Finance APP, Ausun Pharm disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 482 million yuan, a year-on-year decrease of 2.14%; net profit attributable to the parent company was 169 million yuan, a year-on-year decrease of 5.83%; net profit excluding non-recurring gains and losses was 151 million yuan, a year-on-year decrease of 12.29%; basic earnings per share were 0.20 yuan

Ausun Pharm released its semi-annual performance report, with a net profit attributable to the parent company of 169 million yuan, a year-on-year decrease of 5.83%

000813

688302

688136

603716

Innovative drug concept stocks collectively fell, Ausun Pharm hit the limit down, SDKX dropped over 10%, Thalys, DEZHAN HEALTHCARE, and Hinova had significant declines

DEZHAN HEALTHCARE

Hinova

SDKX

Thalys

Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

603127

06127

300347

03347

300683

603538

CRO concept stocks fluctuated lower at the beginning of the trading session, with Ausun Pharm falling over 8%, HITECK dropping over 6%, and Menovo, JOINN, and TIGERMED following suit

JOINN

Tigermed

TIGERMED

HITECK

Menovo

CRO concept stocks fluctuated lower in early trading, Ausun Pharm fell over 8%

300725

The three major indices fluctuated narrowly, with the Shanghai Composite Index down 0.08%, the Shenzhen Component Index down 0.04%, and the ChiNext Index up 0.92%. The CRO, PET copper foil, and semiconductor sectors performed strongly, with Ausun Pharm and Jiuzhou Pharmaceutical hitting the daily limit, and PHARMABLOCK rising over 17%. PET copper foil strengthened in the morning session, with Fangbang Co., Ltd. and Woge Optoelectronics hitting the daily limit. Glyphosate and insurance sectors adjusted, with Xinhua Insurance and China Pacific Insurance falling over 1%

PHARMABLOCK

Midday Review: The ChiNext Index performed strongly, rising nearly 1%, with the pharmaceutical sector showing broad strength

According to the Zhitong Finance APP, Ausun Pharm disclosed its first-quarter report for 2025, reporting revenue of 307 million yuan, a year-on-year increase of 1.90%; net profit attributable to the parent company of 119 million yuan, a year-on-year increase of 5.97%; and net profit excluding non-recurring gains and losses of 112 million yuan, a year-on-year increase of 2.81%. Basic earnings per share are 0.14 yuan

Ausun Pharm released its first-quarter performance, with a net profit attributable to the parent company of 119 million yuan, a year-on-year increase of 5.97%

According to the Zhitong Finance APP, Ausun Pharm announced that the company recently received a Certificate of Suitability (CEP Certificate) issued by the European Directorate for the Quality of Medicines (EDQM) regarding the active pharmaceutical ingredient, Pilocarpine Hydrochloride. Pilocarpine Hydrochloride was first used to treat xerostomia, with the dosage form being tablets

Ausun Pharm: The raw material drug of hydrochloride of lobeliaine has obtained the European CEP certificate

According to the Zhitong Finance APP, Ausun Pharm announced that the company recently obtained a "Loan Commitment Letter" issued by the Taizhou Branch of Bank of China, promising a loan limit of no more than RMB 90 million. The loan will be used solely for repurchasing the company's stock

Ausun Pharm has obtained special loan support for stock repurchase of no more than 90 million yuan

Ausun Pharm(603229.SH)